Ensartinib hydrochloride

Research use only, not for human use.

Ensartinib dihydrochloride is a potent new-generation ALK inhibitor with high activity against CNS metastases and a broad range of known crizotinib-resistant ALK mutations.

Ensartinib dihydrochloride is a potent new-generation ALK inhibitor with high activity against CNS metastases and a broad range of known crizotinib-resistant ALK mutations. It potently inhibits both wild-type ALK and ALK variants (C1156Y, F1174, G1202R, L1196M, S1206R, and T1151 mutants) with in vitro IC50s of <4 nM.(In Vitro):Ensartinib potently inhibits both wild-type ALK and all evaluated ALK variants (C1156Y, F1174, G1202R, L1196M, S1206R, and T1151 mutants) with in vitro IC50s of <4 nM. Besides ALK, ensartinib also potently inhibits GOPC-ROS1, TPM3-TRKA, and TRKC with an IC50 of <1 nM, and inhibits EphA1, EphA2, EphB1 and c-MET with an IC50 of 1-10 nM.

Ensartinib dihydrochloride; X-396 dihydrochloride

Others

Other Targets

mitochondrial cytochrome bc1

——

——

2137030-98-7

634.4

C26H29Cl4FN6O3

>98% (HPLC)

——

Cl.Cl.CC(Oc1cc(nnc1N)C(=O)Nc1ccc(cc1)C(=O)N1CC(C)NC(C)C1)c1c(Cl)ccc(F)c1Cl

——

(-20℃)

With Ice Pack

≥ 2 years